Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vesigenurtucel-L - NightHawk Biosciences

Next Previous
Drug Profile

Vesigenurtucel-L - NightHawk Biosciences

Alternative Names: HS-410; UM-UC-3-gp96-Ig-HLA-A1; vesigenurtacel-L

Latest Information Update: 05 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Miami
  • Class Adjuvants; Cancer vaccines; Cell therapies; Heat shock proteins; Tumour cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer

Most Recent Events

  • 27 Jan 2023 NightHawk Biosciences terminates its licensing agreement with University of Miami for gp96 and TNFRSF25 platforms
  • 03 May 2022 Heat Biologics is now called NightHawk Biosciences
  • 26 Mar 2018 Discontinued - Phase-II for Bladder cancer (Combination therapy, Adjuvant therapy) in USA (Intradermal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top